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Abstract 
Background: Treatment stratification based on bone marrow minimal residual disease (MRD) at set time points has 
resulted in considerably improved survival in pediatric acute lymphoblastic leukemia (ALL). Treatment response is 
assessed using bone marrow samples. MicroRNAs (miRs) easily traffic among fluid spaces and are more stable than 
most other RNA classes. We examined the role of circulating miRs as putative less invasive MRD biomarkers.
Methods: In an exploratory experiment, expression of 46 preselected miRs was studied in platelet-free blood plasma 
samples of 15 de novo, 5 relapsed ALL patients and 10 controls by Custom TaqMan Array Advanced MicroRNA Card. 
Based on their high expression in ALL compared to controls, and on the reduction observed along the induction 
therapy, four miRs were selected for further analyses: miR-128-3p, -181a-5p, -181b-5p and 222-3p. Their expression 
was measured by qPCR at 4 time points in 27 de novo ALL patients treated in the ALL IC-BFM 2009 study.
Results: The expression of all 4 miRs significantly decreased over the first week of therapy (miR-128-3p:  log2 fold 
change − 2.86; adjusted p 3.6 × 10−7; miR-181b-5p:  log2 fold change − 1.75; adjusted p 1.48 × 10−2; miR-181a-5p:  log2 
fold change -1.33; adjusted p 3.12 × 10−2; miR-222-3p:  log2 fold change − 1.25; adjusted p 1.66 × 10−2). However, no 
significant further reduction in miR expression was found after the 8th day of therapy. Measured drop in expression 
of 2 miRs at day 8 strongly correlated with day 15 bone marrow flow cytometry MRD results (miR-128-3p: Pearson’s 
r = 0.88, adjusted p = 2.71 × 10−4; miR-222-3p: r = 0.81, adjusted p = 2.99 × 10−3).
Conclusion: In conclusion, these circulating miRs might act as biomarkers of residual leukemia. MiR-128-3p and miR-
222-3p in blood predict day 15 flow cytometry MRD results 7 days earlier. Although, their sensitivity falls behind that 
of bone marrow flow cytometry MRD at day 15.
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Background
Treatment stratification based on early response to ther-
apy greatly improved survival in pediatric acute lympho-
blastic leukemia (ALL). Treatment response is assessed 
as quantified minimal residual disease (MRD) in bone 
marrow (BM) at set time points. For the last one or two 
decades, MRD assessment has been part of the routine 
clinical practice in the developed world. Flow cytometry 
and/or qPCR based methods are used in various coun-
tries, with sensitivities of  10−3–10−4 and  10−4–10−6, 
respectively [1]. Currently, application of high through-
put sequencing methods are being studied to increase 
MRD sensitivity and to improve patient stratification [2]. 
Compared to individual IgH and TCR qPCR testing, next 
generation sequencing would also save working hours of 
laboratory staff. Whichever method is used, children are 
put under general anesthesia (GA) and undergo BM aspi-
ration for MRD follow up 2–5 times following their diag-
nosis. This is because if little residual leukemia is left, it 
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is most reliably and abundantly found in the BM [1]. GA 
and marrow aspiration, together with preparations and 
related issues (e.g. consenting, starving for anesthesia, 
checks, theatre lists, observations post procedure) put 
quite a burden on children, their families and on hospital 
staff.
MicroRNAs (miRs) are small non-coding RNAs, rang-
ing from 19 to 25 nucleotides in size [3]. Their role is in 
posttranscriptional regulation of mRNA expression. 
MiRs regulate about half of the human genes [4]. Bind-
ing of miRs to their target sequence, with perfect com-
plementarity in seed region and base paring in central 
region, results in mRNA cleavage and degradation. In 
case of less complementarity, translation repression 
is their typical function [5]. There are over 2000 miRs 
known in human [6]. The miR profile is distinct in every 
body fluid. In the blood, for example, platelets have a rep-
ertoire of approximately 750 miRs [7, 8], with the let-7 
family contributing in almost 50% [8]. MiRs can be tis-
sue specific regarding their origin, or there are examples 
when certain miRs are expressed at specific stages of 
ontogenesis or specific stages of cell differentiation [9, 
10].
MiR profiles in normal tissues and in different diseases 
are intensively studied despite of numerous pitfalls [11]. 
MiRs are actively secreted into the extracellular space 
via extracellular vesicles [12]. The secreted miRs partly 
reflect the intracellular miR signature of the source cells, 
but certain miRs are withheld or selectively excreted in 
higher amounts [13]. Compared to mRNAs, miRs are 
much more stable. Some of them persist for 5 days [14, 
15]. MiRs were found to be protected from RNases by 
encapsulation into extracellular vesicles, by complexes 
formed with Argonaute proteins or Nucleophosmin-1 
and by their uptake into lipoproteins [16–18]. As a very 
universal phenomenon, malignant cells secrete higher 
amounts of miRs than healthy cells or tissues [19]. This, 
together with the selective over-secretion of some miRs, 
such as miR-128-3p [20–22], their easy distribution 
among fluid spaces and their stability makes miRs good 
candidates for cancer biomarkers. Indeed, very promising 
such results were published in solid tumors, e.g. in breast 
cancer and non-small cell lung cancer [23]. Some similar 
biomarker studies were published in leukemia, too. These 
focused on the miR signatures in BM, peripheral blood 
(PB) or plasma taken at the time of diagnosis as biomark-
ers of leukemia diagnosis, leukemia subtype, with disease 
characteristics or predictors of prognosis [24–26].
Our aim was to evaluate circulating miRs as biomark-
ers for MRD monitoring in pediatric ALL. Compared to 
the current practice of MRD monitoring, this approach 
would have the great advantage of less invasive sampling 
and no need for GA. Our strategy was to (1) get serial 
patient plasma samples along the induction cycle pro-
spectively, (2) discard platelets very early as the largest 
source of miRs in the blood, (3) choose miRs for analyses 
based on the previously described miR profile of leuke-
mic BM (4) for our first analysis on an exploratory cohort 
with array, and (5) proceed to validation of the selected 
best candidate biomarkers with qPCR on an extended 
patient cohort.
Methods
Patients and samples
We studied 28 pediatric patients with de novo and 5 
patients with 1st relapse of precursor-B cell ALL, age 
1–18 years, diagnosed between 2016 and 2018 at the 2nd 
Department of Pediatrics, Semmelweis University or at 
Heim Pál Children’s Hospital, both in Budapest, Hun-
gary. Informed consent was requested from legal guard-
ians of the patients. The study was approved by the Ethics 
Committee of the Hungarian Medical Research Coun-
cil (60106-1/2015/EKU and 6886/2019/EKU) and con-
ducted according to the principles of the Declaration of 
Helsinki. De novo ALL patients from only three cytoge-
netic subgroups were included: those with hyperdiploidy 
(blast chromosome number ≥ 47), those with t(12;21) 
(p13;q22) alias ETV6/RUNX1 fusion and those with no 
known cytogenetic abnormality (normal findings on a 
set FISH panel targeting frequent ALL rearrangements, 
found to be diploid by flow cytometry DNA index, either 
normal karyotype or unsuccessful karyotyping). Karyo-
type of relapsed patients was not used as selection cri-
teria or for grouping because of the limited number of 
available samples.
Peripheral blood (PB) (3.5 ml) of patients was collected 
at diagnosis and also at days 8, 15 and 33 of the induc-
tion cycle of the ALL IC-BFM 2009 trial protocol. Bone 
marrow (BM) aspirates (1 ml) were collected at diagnosis 
before any treatment and on days 15 and 33. Blood and 
bone marrow samples of relapsed patients were collected 
only at diagnosis. In addition, control PB samples were 
collected from non-leukemic subjects. Control patients 
had one of the following conditions: vitamin D deficiency, 
otitis media, impetigo, hypothyreosis, neurofibromatosis 
type 1, iron deficiency anemia, phimosis.
Preparation of platelet-free plasma (PFP) was carried 
out within 2 h of sampling and was based on the recom-
mendation of the International Society of Thrombosis 
and Haemostasis [27]. Sodium citrate tubes were used 
for all sample types. Samples taken at diagnosis were col-
lected before any steroid or cytostatic treatment would 
have been started for the patient. The use of PFP was cho-
sen based on the fact that platelets have a large repertoire 
of miRs and are the major source of miRs in plasma [28]. 
Whole blood and bone marrow samples were centrifuged 
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at 2500×g for 15  min at 16  °C. Supernatant was trans-
ferred into a new centrifuge tube and centrifuged again 
for 15  min at 16  °C 2500×g. Supernatant was aliquoted 
immediately and stored at − 80 °C until use.
Clinical data were collected during the first month of 
therapy: white blood count at diagnosis, absolute blast 
number at day 8 in peripheral blood, bone marrow flow 
cytometry (FC) MRD at day 15, absolute white blood cell 
count at day 33, absolute lymphocyte count at day 33 and 
FC MRD at day 33. FC MRD was measured in routine 
diagnostics as per the standards of ALL IC-BFM 2009 
study.
Detailed description of patients and samples used is 
provided in Table 1, 2, and 3.
RNA isolation, cDNA synthesis and miR profiling on array
With the aim to find MRD biomarkers, 46 miRs were 
selected for analysis. Only miRs found to be overex-
pressed in blasts in at least two different previously pub-
lished studies were chosen (Table 4).
MiRNeasy Serum/Plasma Kit (Qiagen, Hilden, Ger-
many) was used for RNA isolation from defrosted PFP 
samples. Synthesis of cDNA was carried out using 
TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo 
Table 1 Samples analyzed on TaqMan low density array and with advanced qPCR
Sampling dates are marked as days of the induction chemotherapy cycle
BM bone marrow, PB peripheral blood
a Normal karyotype: no alteration on FISH, DNA index diploid and cytogenetics normal or unsuccessful
Subgroups Discovery population Extended population
BM at Day 
0 (n)
PB at Day 
0 (n)
PB at Day 
8 (n)
PB at Day 33 
(n)
PB at Day 
0 (n)
PB at Day 
8 (n)
PB at Day 15 
(n)
PB at Day 
33 (n)
De novo ALL
 Hyperdiploid 3 3 3 2 8 8 8 8
 t(12;21) 6 6 3 2 9 9 9 9
 Normala 6 6 3 2 10 10 10 9
Relapsed ALL 5 5
Control 10 10
SUM 20 30 9 6 37 27 27 26
Table 2 Characteristics of the population studied on custom TaqMan low density array
a Normal: no alteration on FISH, DNA index diploid and cytogenetics normal or unsuccessful
Subgroups Age in years median (range) Number of patients (n) Male (n) Female (n)
De novo ALL
 Karyotype: hyperdiploid 3.1 (2.0–3.7) 3 1 2
 t(12;21) 3.6 (3.1–4.6) 6 3 3
 Karyotype:  normala 3.1 (1.5–5.3) 6 4 2
Relapsed ALL 10.4 (6.3–18.8) 5 3 2
Total number of patients 3.9 (1.5–18.8) 20 11 9
Control 4.4 (1.6–15.1) 10 6 4
Table 3 Characteristics of the population studied by advanced qPCR method
a Normal: no alteration on FISH, DNA index diploid and cytogenetics normal or unsuccessful
Subgroups Age in years median (range) Number of patients (n) Male (n) Female (n)
De novo ALL
 Karyotype: hyperdiploid 3.8 (2.0–13.7) 8 1 7
 t(12;21) 3.1 (2.2–4.6) 9 6 3
 Karyotype:  normala 4.9 (1.5–17.3) 11 9 2
Control 4.4 (1.6–15.1) 10 6 4
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Fisher Scientific, Waltham, MA, USA) according to the 
protocol supplied by the manufacturer.
MiR profiling of 65 PFP samples from 20 ALL patients 
(15 de novo and 5 relapsed ALL) and 10 control sam-
ples was performed using Custom TaqMan Advanced 
Low Density miRNA Array (TLDA) Card (Thermo 
Fisher Scientific, Waltham, MA, USA). Measurements 
were carried out using QuantStudio 7 Flex Real-Time 
PCR System (Thermo Fisher Scientific, Waltham, MA, 
USA). GeNorm algorithm was used to calculate the gene 
expression stability measure for each potential reference 
miR, based on the average pairwise variation between all 
candidate reference miRs. As a validation, NormFinder 
algorithm was also used which takes intra- and inter-
group variability into account. Based on these analyses, 
miR-484 was selected for normalizing, and the ΔCt value 
was calculated for each miR. Four samples measured 
in duplicates on TLDA Card and correlated very highly 
(Pearson’s r = 0.981 (CI 95% 0.974–0.986), p < 10−16).
Quantitative real‑time PCR
Based on the results of TLDA cards, 4 candidate miRs 
were selected for further investigation on an extended 
population using Advanced qPCR methodology. Quanti-
tative Real-time PCR TaqMan Advanced miRNA assays 
were used according to the manufacturer’s instruction 
(Thermo Fisher Scientific, Waltham, MA, USA). Thermo 
Fisher 7900HT Fast Real-Time PCR system was used for 
real-time quantitative PCR measurement (Thermo Fisher 
Scientific, Waltham, MA, USA). PFP samples originated 
from peripheral blood of 28 patients with ALL and 10 
controls were measured, in total 110 samples (Table 3 for 
details). Detection of 5 miRs (miR-181a-5p, miR-81b-5p, 
miR-128-3p, miR-22-3p and control miR-484) were per-
formed in duplicates (correlation between duplicates was 
calculated: Pearson’s r = 0.998, p < 2.2*10−16). Correlation 
between Advanced qPCR and TLDA measurements was: 
Pearson’s r = 0.873, p = 3.19*10−44.
Statistical analysis
All statistical analyses were performed using R statisti-
cal software (R Foundation for Statistical Computing, 
Vienna, Austria; version 3.5.1). To select suitable ref-
erence miRs for normalization, the geNorm and Nor-
mFinder algorithms of the NormqPCR [41] package 
was used. Statistical differential expression of miRs was 
determined by the Limma [42] package. For that, a linear 
model was fitted for each gene based on the subgroup of 
the patients or the different sampling times. The gender 
of the patients was used as a coefficient in both cases. 
Then, moderated t-statistics and log-odds of differential 
expression were calculated by empirical Bayes modera-
tion of the standard errors towards a common value. The 
resulting p-values obtained were corrected for multiple 
testing using the Benjamini–Hochberg procedure. Genes 
were considered to be differentially expressed when the 
adjusted p-value false discovery rate was below 0.05. 
Pearson correlation coefficients were calculated to evalu-
ate the correlation between the flow cytometry MRD 
results and the  log2 transformed expression level or fold 
change of miRs, respectively. In order to deal with multi-
ple comparisons, the p-values were adjusted by the Ben-
jamini–Hochberg false discovery rate method with type I 
error rate of 5%.
Results
MiR expression pattern of the exploratory cohort on array
Expressions of 46 selected miRs were measured in PFP 
samples of de novo and relapsed pediatric precursor-
B acute lymphoblastic leukemia patients and controls 
Table 4 The 46 microRNAs selected for custom TaqMan low density array
MicroRNA Field of research References
Cel-miR-39 Exogenous, spike-in control [29, 30]
miR-103a-3p, miR-638 miR-484, miR-30d-5p, miR-16-5p Candidate reference microRNAs [31–33]
let-7a-5p, let-7f-5p Platelet origin microRNAs [8]
miR-128-3p, miR-181b-5p Bone marrow cells [34, 35]
miR-222-3p, miR-223-3p, miR-361-3p, miR-374a-5p, miR-501-5p, miR-511-5p, miR-532-5p, miR-
660-5p, miR-98-5p
Hyperdiploid ALL [36]
miR-20a-5p, miR-93-5p Different ALL cell lines [37]
miR-100-5p, miR-125b-5p, miR-126-3p, miR-320a, miR-383-5p, miR-494-3p, miR-629-5p, miR-99a-5p t(12;21) ALL [31, 35, 36, 38]
miR-17-5p, miR-181a-5p, miR-181b-5p, miR-181c-5p, miR-320a, miR-342-3p, miR-106a-5p, miR-1290 Relapsed ALL [34, 35, 38–40]
miR-146a-5p, miR-155-5p, miR-222-3p, miR-34a-5p, miR-511-5p, miR-99a-5p Circulating microRNAs in  
pre-B ALL
[31]
miR-632, miR-654-5p T and dendritic cell lines [18]
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Fig. 1 TaqMan low density array miR expression, comparison of ALL subgroups and controls. The heatmap displays the expression pattern of 
microRNAs measured in platelet-free plasma derived from bone marrow and peripheral blood samples of pediatric ALL patients. The horizontal 
axis shows the origin of samples in different subgroups (normal karyotype: no alteration on FISH, DNA index diploid and cytogenetics normal or 
unsuccessful; HD: hyperdiploid subgroup), the day of sampling in relation to start of treatment. The vertical axis shows the 44 previously selected 
microRNA repertoire. miR-484 was used as normalizing miR. Expression of further 2 miRs was not detected in any samples. The scale shows the 
normalized  log2 transformed expression levels. Yellow indicates microRNA down-expression, red indicates overexpression compared to the 
normalizing miR
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on custom TaqMan low density array (TLDA). See the 
results illustrated in Figs. 1, 2, and 3. There was no sig-
nificant correlation between miR expressions of the bone 
marrow and the peripheral blood (adjusted p > 0.05, data 
not shown).
The expressions of 19 miRs in ALL PB PFP at diagno-
sis were significantly different compared to the control 
samples (p < 0.05). In line with our selection criteria, 18 
miRs showed higher expression, while one miR showed 
downregulation in leukemic patients (Fig.  2). Different 
karyotype (hyperdiploid, t(12, 21), normal) subgroups 
were separately compared to the control PFP samples. 
Five miRs were significantly upregulated in every sub-
group: miR-128-3p, miR-146a-5p, miR-181b-5p, miR-
222-3p and miR-532-5p (p < 0.05). There was no unique 
miR expression pattern in subgroups of patients based on 
our TLDA measurements. Platelet originated miRs (let-
7a-5p and let-7f-5p) were not significantly upregulated or 
downregulated compared to the control samples.
When miR expression differences were analysed 
between day 0 and day 33 of therapy in PB PFP, 4 miRs 
showed significantly lower expression at day 33: miR-
128-3p, miR-181a-5p, miR-181b-5p, miR-222-3p. These 
4 miRs were further investigated by Advanced qPCR on 
the extended cohort.
MiR expression pattern of the extended cohort 
by advanced qPCR
Relative expression levels of the 4 selected miRs were first 
compared between ALL day 0  PB PFP samples and PB 
PFP of non-leukemic controls. ALL subgroups of differ-
ent karyotypes were examined separately as well as the 
whole ALL group (Table 5).
Changes of PB PFP miR expression along the induction 
cycle were analyzed in paired tests. Higher expression 
of all 4 miRs identified on TLDA (miR-128-3p, miR-
181a-5p, miR-181b-5p and miR-222-3p), was validated in 
the extended study population.
Measured by qPCR in this larger cohort, the expression 
of all four miRs decreased significantly after the start of 
treatment. However, no further significant drop could be 
demonstrated after day 8 with regards to any of the miRs 
(Fig.  4; Table  6). This question was also explored in the 
three ALL cytogenetic subgroups separately, and simi-
lar trends were found (Fig. 5). The best correlations and 
tendencies were seen with miR-181b-5p, miR-128-3p 
expression within the normal karyotype group, but no 
significant change was found after day 8 in any karyotype 
subgroup or any miR.
Association of miR qPCR results with other MRD methods 
and prognostic factors
In order to further examine the value of the 4 selected 
miRs as MRD biomarkers, we tested their associations 
with results of other MRD measurement methods and 
with various risk factors: induction day 15 bone mar-
row flow cytometry MRD (the gold standard method to 
measure early treatment response in ALL-IC studies), 
day 8 absolute blast count in peripheral blood film by 
microscopic cytomorphology (also recorded in the ALL-
IC and BFM studies), risk group stratification (based on 
age, initial white blood cell count (WBC), cytogenetics 
and early treatment response as per ALL-IC 2009) as well 
as end of induction absolute lymphocyte count (recently 
suggested as a prognostic marker) [43, 44]. All these 
questions were analyzed in the whole ALL group and in 
cytogenetic subgroups. See the significant associations 
highlighted in Table 7 and further results and details in 
Additional file 1.
All patients were MRD negative on day 33 bone mar-
row flow cytometry, hence this association could not be 
analyzed. To test if the blood WBC influences PB PFP 
miR expression causing bias, we checked this association 
on day 0 and day 33 and found no correlation.
The predictive accuracy of microRNAs to differenti-
ate patients with high MRD (defined as induction day 15 
bone marrow flow cytometry MRD greater than 1%) ver-
sus low MRD (< 1%) was also assessed by ROC analysis 
and by calculating the area under the receiver operating 
characteristic curve (AUC). MiR-128-3p had the high-
est predictive accuracy (AUC = 0.91) and miR-222-3p 
showed also high predictive accuracy (AUC = 0.79) 
(Fig. 6). See the full result set of ROC analyses in Addi-
tional file 2.
Discussion
We hypothesized that circulating miRs may be used as 
biomarkers of residual leukemia with the advantage of 
less invasive sampling for follow-up, compared to bone 
marrow aspirate based tests in present practice. We 
focused on pediatric precursor-B cell ALL patients.
Platelet-free plasma (PFP) derived from peripheral 
blood (PB) was chosen for analyses. In the first step, 46 
candidate miRs were examined on a discovery popula-
tion of de novo plus relapsed ALL patients and controls. 
Four miRs were selected for further analyses based on 
higher expression compared to controls and based on 
their decreasing expression by the end of induction: miR-
128-3p, miR-181a-5p, miR-181b-5p and miR-222-3p. 
These four miRs were then tested by advanced qPCR at 
4 time points along the induction cycle of an extended 
cohort of de novo ALL patients. Over the first week, 
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Fig. 2 MiR expression pattern in ALL and control PB PFP samples measured by TLDA. Case indicates de novo and relapsed ALL day 0 PB PFP samples, 
control indicates non-leukemic PB PFP samples. Data obtained on TLDA measurements. Box: the 2nd and 3rd quartiles; thick line in the box: median; 
lower whiskers: minimal value if there are no low outrange values, or Q1 − 1.5*IQR; upper whiskers: maximum value if there is no upper outlier, or 
Q3 + 1.5*IQR; dots: outliners, lines above the boxes: significant correlation (p < 0.05); ***p value: 0–0.001; **p value: 0.001–0.01; *p value: 0.01–0.05
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Fig. 3 MiR expression in de novo and relapsed ALL PB PFP at the day of diagnosis (by TLDA). Box: the 2nd and 3rd quartiles; thick line in the box: 
median; lower whiskers: minimal value if there are no low outrange values, or Q1 − 1.5*IQR; upper whiskers: maximum value if there is no upper 
outlier, or Q3 + 1.5. No significant differences were found
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the expression of all four miRs dropped significantly 
but there was no relevant further decrease at later time 
points. Correlation of miR expression with standard 
MRD results and risk factors could be demonstrated. On 
ROC analyses, the drop of normalized miR expression 
(day 8 or day 15 compared to day 0) performed better 
than the normalized expressions themselves at any given 
time points. Day 8 miR expressions performed somewhat 
Table 5 miR expressions in diagnostic ALL samples compared to controls (PB PFP samples, advanced qPCR results)
Values in the table indicate the average  log2 fold change between cases and controls
NS no significant correlation
a Normal karyotype: no alteration on FISH, DNA index diploid and cytogenetics normal or unsuccessful
Subgroups miR‑128‑3p  log2FC  
(adj. p value)
miR‑181a‑5p  log2FC  
(adj. p value)
miR‑181b‑5p  log2FC  
(adj. p value)
miR‑222‑3p 
 log2FC (adj. p 
value)
Karyotype: hyperdiploid 3.39 (7.05*10−4) NS NS 2.09 (4.06*10−2)
Karyotype: t(12;21) 5.93 (9.59*10−10) 2.56 (1.38*10−2) 3.84 (2.26*10−4) 3.34 (2.21*10−4)
Karyotype:  normala 4.23 (1.78*10−5) 3.45 (5.35*10−4) 4.31 (4.73*10−5) 2.63 (4.76*10−3)
Whole cohort 4.52 (3.48*10−9) 2.46 (2.11*10−3) 3.46 (4.73*10−5) 2.68 (2.15*10−4)
Fig. 4 MiR expressions in PB PFP during the first month of therapy (by TaqMan Advanced qPCR). Box: the 2nd and 3rd quartiles; thick line in the 
box: median; whiskers: minimum and maximum values if there are no outrange values, or Q1 − 1.5*IQR; dots: outliers, lines above the boxes: 
significant correlation (p < 0.05); ***p value: 0 ≤ p < 0.001, **p value: 0.001 ≤ p < 0.01, *p value: 0.01 ≤ p < 0.05
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better than day 15 miR expressions. After all, the day 0 
to day 8 change in normalized expression of miR-128-3p 
and miR-181b-5p came out as best MRD-biomarkers.
To summarize our results, the selected circulating miRs 
can indeed be used as biomarkers of residual leukemia 
burden but are less sensitive than the day 15 bone mar-
row flow cytometry MRD measurement, the standard 
response measurement in ALL-IC. We know it from flow 
cytometry (as well as IgH and TCR based qPCR) MRD 
measurements that in reality, a monotonous multiple-log 
reduction occurs in the bone marrow blast percentage 
from day 0, through day 8 and day 15 to day 33 along the 
induction cycle [45–47]. By blood PFP miR measurement 
in our study, only a day 0 to day 8 reduction could be 
demonstrated. The most plausible explanation is that the 
overexpression of miRs originated from residual leuke-
mic cells is measurable in the blood plasma but the noise 
(baseline miR expressions and their variability) is too 
high to allow for a sensitive leukemia follow-up. Indeed, 
the expression of the same miRs could be detected in the 
serum of healthy adults [48]. It is difficult to tell what this 
background noise is related to. The general understand-
ing about miRs is that these participate in many regula-
tion pathways in normal physiology. In microRNA Target 
Prediction Database (miRDB.org), an online database 
miR-128-3p has 1254 predicted targets while miR-222-3p 
has 619, miR-181a-5p and miR-181b-5p have 1408 pre-
dicted targets [49].
Our results are in parallel with findings of multiple 
studies which examined miR expression in leukemic cells 
[3, 34, 35, 50–55]. In these studies, miRs were extracted 
from whole bone marrow or from whole blood of pedi-
atric- or partly pediatric-ALL patients, from mononu-
clear cells separated of the above samples, or from ALL 
cell lines. Very different sets of miRs were investigated, 
all partially overlapping with our selection. The 4 miRs 
chosen in our study were unanimously described as being 
overexpressed in ALL blasts. The reported rate of overex-
pression compared to healthy controls or to ALL patients 
in remission spread between 1.3 and 500 times, with very 
diverse normalizing RNAs used. The findings supported 
by most evidence are the overexpression of miR-128 and 
miR-181-family members. Many other overexpressed 
miRs were reported in ALL, e.g. let-7b, miR-222, miR-
181b [31, 34].
Among the cellular miR studies, some reported dif-
ferent miR expression patterns in ALL cytogenetic sub-
groups [31, 35, 36, 50], which could not be demonstrated 
in our present study in PFP. Interestingly, authors disa-
gree if the miR expression pattern of bone marrow and 
peripheral blood are similar [50, 51] or different [52] in 
intrapersonal comparisons. We did not find strong corre-
lation between marrow PFP and blood PFP miR expres-
sions in our TLDA results (adjusted p > 0.05, data not 
shown).
Table 6 miR expression changes in peripheral blood PFP during the 1st month of chemotherapy
NS no significant correlation
a Normal karyotype: no alteration on FISH, DNA index diploid and cytogenetics normal or unsuccessful
Subgroups miR miR expression changes between sampling dates  log2FC (adjusted p)
Day 8–day 0 Day 15–day 0 Day 33–day 0
Whole cohort miR-128-3p − 2.86 (3.6*10−7) − 3.15 (3.87*10−7) − 3.60 (7.77*10−10)
miR-181a-5p − 1.33 (3.12*10−2) − 0.93 (NS) − 2.08 (1.01*10−3)
miR-181b-5p − 1.75 (1.48*10−2) − 2.39 (2.05*10−3) − 2.76 (8.78*10−5)
miR-222-3p − 1.25 (1.66*10−2) − 1.03 (NS) − 1.94 (2.09*10−4)
Karyotype:  normala miR-128-3p − 2.49 (2.87*10−3) − 2.29 (3.09*10−2) − 2.99 (4.15*10−4)
miR-181a-5p − 2.58 (2.87*10−3) − 1.79 (NS) − 3.82 (1.16*10−5)
miR-181b-5p − 2.72 (2.87*10−3) − 3.44 (1.51*10−3) − 4.50 (7.63*10−7)
miR-222-3p − 1.23 (NS) − 0.98 (NS) − 2.45 (2.41*10−3)
Karyotype: t(12;21) miR-128-3p − 4.33 (2.20*10−8) − 4.62 (1.74*10−8) − 4.42 (2.12*10−8)
miR-181a-5p − 1.72 (NS) − 0.71 (NS) − 1.13 (NS)
miR-181b-5p − 2.49 (4.11*10−2) − 2.42 (NS) − 2.02 (NS)
miR-222-3p − 2.15 (1.16*10−2) − 1.59 (NS) − 1.82 (3.39*10−2)
Karyotype: hyperdiploid miR-128-3p − 1.39 (NS) − 2.21 (NS) − 3.31 (NS)
miR-181a-5p − 1.16 (NS) − 0.16 (NS) − 1.01 (NS)
miR-181b-5p 0.82 (NS) − 0.98 (NS) − 1.42 (NS)
miR-222-3p 0.08 (NS) − 0.20 (NS) − 1.47 (NS)
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Fig. 5 MiR expression during the first month of the therapy in cytogenetic subgroups of ALL (by qPCR). a Normal karyotype (no alteration on FISH, 
DNA index diploid and cytogenetics normal or unsuccessful); b hyperdiploid subgroup; c t(12;21). Box: the 2nd and 3rd quartiles; thick line: median; 
lower whiskers: minimal value if there are no low outlier values, or Q1 − 1.5*IQR; upper whiskers: maximum value if there is no upper outlier, or 
Q3 + 1.5*IQR; dots: outliners. Lines above the boxes: significant correlation (p < 0.05); ***p value: 0–0.001, **p value: 0.001–0.01, *p value: 0.01–0.05
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Three publications are available that evaluated circu-
lating miRs in pediatric ALL. These studied plasma or 
serum unlike our present study (PFP samples). The iden-
tified miRs are different from ours and from each other, 
however, all three papers conclude that circulating miRs 
offer a very sensitive and specific diagnostic tool to differ-
entiate pediatric precursor-B cell ALL cases from healthy 
controls [31, 56, 57]. We are not aware of any previous 
study which would have evaluated PFP miR expression in 
pediatric ALL, or would have evaluated circulating miRs 
as ALL MRD biomarkers. There are encouraging such 
publications on patient cohorts of other malignancies, 
though [58, 59].
Our study has special strengths when compared to 
other papers. A possible bias by platelets—as massive 
sources of circulating miRs—could be ruled out because 
no association of leukemia MRD and platelet originated 
miRs was found despite the wide range of platelet count 
of our patients. As no correlation could be detected 
between PFP miR expression levels and WBC either 
on day 0 (all patients with full blown ALL, before treat-
ment) or day 33 (all the patients were MRD negative with 
bone marrow flow cytometry), we are convinced that the 
measured miR expressions were not primarily influenced 
by healthy leukocytes or blasts in the peripheral blood.
Mir-181 might contribute to leukemogenesis and 
relapse [35], it is the inducer of Wnt/β-catenin signaling 
pathway. The uncontrolled pathway causes leukemia by 
stimulating cell proliferation. It has been demonstrated 
using ALL-derived cell lines and bone marrow samples 
of patients with ALL that miR-181a-5p targets and inac-
tivates Wnt antagonist WIF1 (Wnt inhibitory factor-1) 
[60].
Regarding the biology in the background, miR-128 was 
found to inhibit or promote tumor proliferation in several 
tumors and its proved target genes alter cancer-related 
biological processes [61]. Its expression was higher in 
ALL cell lines [51], in patients with poor-prognosis ALL 
[51], in bone marrow samples of children with ALL at 
diagnosis, at relapse, but not in remission [35]. Expres-
sion of miR-128 decreased during therapy [51]. One of 
the predicted putative targets of miR-128b is BMI1, a 
transcriptional factor which is important in hematopoi-
etic stem cells and leukemia stem-cell self-renewal [35, 
61]. In silico predictions suggest that miR-128 and miR-
181 are among the major regulators of lymphoid differen-
tiation. These miRs may uphold early progenitor cells at 
early stem-progenitor stage, prevent their further differ-
entiation towards more mature cells by regulating mol-
ecules having crucial role in early steps of hematopoiesis. 
MiR-222, most likely, blocks hematopoietic differen-
tiation at terminal stages [62]. Chromosomal location 
of miR-222 is close to Xp11.3 and its target is C-KIT’s 
3′UTR. C-kit is a tyrosine kinase receptor with a role in 
cell differentiation and growth. It is expressed in hemat-
opoietic stem cells and progenitor cells [63].
Lacking standards regarding normalizing miRs and 
only partial correlation of various PCR based methods 
which are widely known difficulties of RNA and miR lab 
methodologies contribute to the limitations of this paper. 
Still, we were able to prove our points via both meth-
ods applied. Our sample collection started in 2016, so it 
was not possible to correlate miR expressions to patient 
survival yet, and the cohort would also be small for that 
analysis. Given the candidate miR approach used, the 
existence of a better miR biomarker of leukemia MRD 
cannot be ruled out.
Table 7 Associations between miR expression changes and MRD parameters or risk factors
In these analyses, the dependent variable is the normalized miR expression change between the time points compared, all measured in PB PFP. Fold change indicates 
change in the normalized miR expression between the two time points, the median of these values are provided. Pearson’s r indicates the correlation between the 
dependent and the independent variables. Adjusted p refers to the statistical significance of the Pearson’s correlation
a Normal karyotype: no alteration on FISH, DNA index diploid and cytogenetics normal or unsuccessful
miR Time points Fold change Independent variable Patient subgroup Pearson’s r Adjusted p
miR-128-3p Day 8 vs day 0 0.107 Flow cytometry MRD in day 15 bone marrow Whole cohort 0.88 2.71*10−4
miR-222-3p Day 8 vs day 0 0.267 Flow cytometry MRD in day 15 bone marrow Whole cohort 0.81 2.99*10−3
miR-128-3p Day 8 vs day 0 0.149 Flow cytometry MRD in day 15 bone marrow Normal  karyotypea 0.99 7.53*10−4
miR-222-3p Day 8 vs day 0 0.270 Flow cytometry MRD in day 15 bone marrow Normal  karyotypea 0.97 2.74*10−2
miR-222-3p Day 8 vs day 0 0.190 Absolute peripheral blast count on day 8 t(12;21) 0.96 4.63*10−2
miR-181b-5p Day 33 vs day 0 0.061 Absolute lymphocyte count on day 33 Normal  karyotypea 0.95 2.98*10−2
miR-222-3p Day 33 vs day 0 0.156 Absolute lymphocyte count on day 33 Normal  karyotypea 0.94 3.87*10−2
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Conclusion
In summary, circulating miR-128-3p and miR-181b-5p 
expression behave as biomarkers of residual leukemia in 
pediatric ALL. However, these are less sensitive than cur-
rent standards of patient follow-up.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1296 7-019-2114-x.
Fig. 6 ROC curve analyses of miR expression changes between day 0 and 8. ROC curves showing the predictive accuracy of miR expression 
changes between day 0 and 8 to differentiate patients with high and low MRD. Area under the ROC curve (AUC) and its confidence interval are 
indicated. Patients with high MRD are defined as induction day 15 bone marrow flow cytometry MRD ≥ 1%. a miR-181b-5p; b miR-181a-5p; c 
miR-128-3p; d miR-222-3p
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Additional file 1. Associations between miR expression changes and 
MRD parameters or risk factors. In these analyses, the dependent vari-
able is the normalized miR expression change between the time points 
compared, all measured in PB PFP. Fold change indicates change in the 
normalized miR expression between the two time points, the median of 
these values are provided. Pearson’s r indicates the correlation between 
dependent and independent variables. Adjusted p refers to the statistical 
significance of the Pearson’s correlation. *Normal karyotype: no alteration 
on FISH, DNA index diploid and cytogenetics normal or unsuccessful.
Additional file 2. ROC curve analysis. The predictive accuracy of miRs to 
differentiate patients with high MRD (defined as induction day 15 bone 
marrow flow cytometry MRD greater than 1%) versus low MRD (< 1%) was 
assessed by ROC analysis and by calculating the area under the receiver 
operating characteristic curve (AUC).
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